Impax regains rights to Parkinson's disease drug candidate

04/30/2013 | Reuters

Impax Laboratories will regain the rights to develop and market IPX066, an experimental Parkinson's disease drug, in certain countries after agreeing to end a collaboration deal with GlaxoSmithKline. The firms cited regulatory and commercialization delays in countries where GSK holds the right to sell the drug, known as Rytary in the U.S., as the reason for the deal's termination.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA